株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗菌薬耐性・薬剤耐性 (AMR) 診断:技術・病原菌別の動向・予測 (2020-2024年)

Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024

発行 Howe Sound Research 商品コード 928144
出版日 ページ情報 英文 228 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.59円で換算しております。
抗菌薬耐性・薬剤耐性 (AMR) 診断:技術・病原菌別の動向・予測 (2020-2024年) Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024
出版日: 2020年03月07日 ページ情報: 英文 228 Pages
概要

抗菌薬耐性・薬剤耐性 (AMR) によってもたらされる脅威の低減においては診断技術が主導的役割を果たしており、遺伝子シーケンシングを超えた新しい診断技術が複数開発されています。

当レポートでは、抗菌薬耐性・薬剤耐性 (AMR) の診断の市場調査し、市場構成、AMRの概要、主な薬剤耐性菌(6種) および診断技術の概要、企業間の各種展開、技術開発の動向、主要事業者のプロファイル、市場の展望などをまとめています。

第1章 イントロダクション・市場の定義

第2章 市場概要

  • 参入事業者・機関の役割・影響
    • 医薬品製造業者:大手・医薬品
    • 医薬品製造業者:ジェネリック
    • CRO・CMO
    • 体外診断
    • 医薬品マーケティング
    • バイオテクノロジー
    • 規制当局
  • 抗菌薬耐性・薬剤耐性 (AMR) について
  • 新たな抗生剤・技術の道程の変化
  • AMRにおける診断の重要性

第3章 AMRの市場機会

  • 大規模な市場機会
    • 薬剤耐性肺炎球菌 (DRSP)
    • 薬剤耐性カンピロバクター (DRC)
    • クロストリジウムディフィシル (CD)
    • メチシリン耐性黄色ブドウ球菌 (MRSA)
    • 薬剤耐性淋菌 (DRNG)
    • 薬剤耐性サルモネラ菌 (DRNTS)
  • 診断技術の開発機会
    • マルチプレックス vs. POC/迅速
    • 複数の病原菌からすべての病原菌へ:次世代
    • シーケンシング無しでの遺伝子配列診断
    • 耐性マーカー、など
  • 抗生物質耐性:近年の展開
    • 食中毒菌による感染症の治療が困難に
    • ほこりによる抗生物質耐性遺伝子を媒介
    • Qiagen:AMRデータベースをローンチ
    • 淋病の抗生物質耐性試験:FDAのBT指定を獲得
    • Qiagen・Ares Genetics:AMRバイオインフォマティクスでライセンシング
    • OpGen:AMR Gene Panelで初めて510 (k) を申請
    • Curetis子会社Ares Genetics:Sandozと協力、など

第4章 主要なバイオテクノロジー企業とその技術

  • 1928 Diagnostics
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Beckman Coulter, Inc
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (now Danaher)
  • Curetis N.V. / Curetis GmbH
  • Day Zero Diagnostics
  • Enzo Life Sciences, Inc.
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • GenePOC Diagnostics
  • Great Basin Corporation
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Millipore Sigma
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Roche Diagnostics
  • SeLux Diagnostics
  • Sense Biodetection
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc

第5章 世界市場:国別

第6章 世界市場:病原菌別

  • DRSP
  • DRC
  • CD
  • MRSA
  • DRNG
  • DRNTS

第7章 AMR診断市場:技術別

  • 細菌培養
  • 免疫測定
  • ポリメラーゼ連鎖反応 (PCR)
  • 遺伝子シーケンシング
  • 質量分析装置
  • 迅速診断・POC診断・その他

第8章 AMR診断の将来性・ビジョン

目次

OVERVIEW:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Antimicrobial Resistance - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2. Defining the Opportunity
    • 1.2.1. Revenue Market Size
  • 1.3. Methods and Sources
    • 1.3.1. Authors
    • 1.3.2. Sources
  • 1.4. U.S. Antibiotic Markets - Perspective
    • 1.4.1. U.S. Outpatient Use of Antibiotics
    • 1.4.2. U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1. Market Players - Roles & Impacts
    • 2.1.1. Drug manufacturers - Larger/pharmaceutical
    • 2.1.2. Drug manufacturers - Generic
    • 2.1.3. Contract Research and Manufacturing
    • 2.1.4. In Vitro Diagnostics Industry
    • 2.1.5. Drug Marketing Companies
    • 2.1.6. Biotechnology Companies
    • 2.1.7. Regulatory Bodies
  • 2.2. Understanding Antimicrobial Resistance
    • 2.2.1. What is Antimicrobial Resistance (AMR)
    • 2.2.2. Bacteria and Other Microbes
    • 2.2.3. The History of Antibiotics
    • 2.2.4. The Role of Animal Husbandry
    • 2.2.5. The Implications of Horizontal Transfer
    • 2.2.6. The Threat of AMR
  • 2.3. The Changing Road to New Antibiotics & Technologies
  • 2.4. The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1. The Key Large Market Opportunities in AMR
    • 3.1.1. Streptococcus Pneumoniae (DRSP)
    • 3.1.2. Campylobacter (DRC)
    • 3.1.3. Clostridium Difficile (CD)
    • 3.1.4. Staphylococcus aureus (MRSA)
    • 3.1.5. Neisseria gonorrhoeae (DRNG)
    • 3.1.6. Salmonella (DRNTS)
  • 3.2. Diagnostic Technology Development Opportunities
    • 3.2.1. What's Wrong with Microbiology
    • 3.2.2. The Features Battleground of Infectious Disease Diagnostics
    • 3.2.3. Multiplex vs. POC/Rapid
    • 3.2.4. The Miracle of Genetics
    • 3.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 3.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing.
    • 3.2.7. Markers of Resistance.
    • 3.2.8. What Happens to the Microbiology Lab?
  • 3.4. Antibiotic Resistance Recent Developments
    • Importance of These Developments
    • How to Use This Section
    • Infections with foodborne bacteria becoming harder to treat
    • Dust is sharing antibiotic resistance genes
    • Report predicts drug resistance likely to kill 400,000
    • New method to test for infection resistance.
    • Qiagen launches AMR database
    • Antibiotic resistance test for gonorrhea gets FDA breakthrough
    • Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics
    • OpGen to File First 510(k) for AMR Gene Panel
    • Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR
    • GeneCapture to determine antibiotic sensitivity in an automated rapid portable device
    • Quick identification of multidrug-resistant pathogens
    • OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
    • Metagenomics Enables Researchers to Uncover Drug Resistance Genes
    • Rapid detection of multi-drug-resistant bacteria
    • Improved Diagnostics Fail to Halt the Rise of Tuberculosis
    • High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
    • New solution for diagnosing antibiotic-resistant bacteria
    • MALDI-TOF - Results in Minutes not Days
    • CRISPR Tool Used to Uncover Infections
    • Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
    • BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
    • LiDia® BSI Detects Pathogens and Antimicrobial Resistance
    • New tool can Track Resistant Malaria
    • Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
    • Longitude Funds for POC Tests
    • New test can identify dangerous bacteria with resistance to last-resort antibiotic
    • bioMérieux receives FDA clearance for expanded pathogen identification capability
    • OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
    • Hospital Plumbing Harbors Antibiotic Resistant Bacteria
    • Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
    • Curetis Gets Singapore Approval for Pneumonia Test
    • PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
    • Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

4. Key Biotechnology Companies and Their Technology

  • 1928 Diagnostics
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Beckman Coulter, Inc
  • Becton, Dickinson and Company
  • Binx Health
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (now Danaher)
  • Curetis N.V. / Curetis GmbH
  • Day Zero Diagnostics
  • Enzo Life Sciences, Inc.
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • GenePOC Diagnostics
  • Great Basin Corporation
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Millipore Sigma
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Roche Diagnostics
  • SeLux Diagnostics
  • Sense Biodetection
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc

5. The Global Market

  • 5.1. Global Market by Country

6. Global Market by Pathogens

  • 6.1. Global Market by Pathogens
  • 6.2. DRSP
  • 6.3. DRC
  • 6.4. CD
  • 6.5. MRSA
  • 6.5. DRNG
  • 6.6. DRNTS

7. AMR Diagnostics by Technology

  • 7.1. Global Market by Technology
  • 7.2. Bacterial Culture
  • 7.3. Immunoassay
  • 7.4. Polymerase Chain Reaction
  • 7.5. Genetic Sequencing
  • 7.6. Mass Spectrometer
  • 7.7. Rapid, POC and Other

8. Vision of the Future of AMR Diagnostics

Table of Tables

  • Table 1: USA - Outpatient Use of Antibiotics by Class
  • Table 2: USA - Outpatient Use of Antibiotics Top 5
  • Table 3: Market Players by Type
  • Table 4: Known Human Pathogenic Diseases
  • Table 5: The Key Market Opportunities
  • Table 6: Market Potential DRSP Diagnostic
  • Table 7: Market Potential DRC Diagnostic
  • Table 8: Market Potential CD Diagnostic
  • Table 9: Market Potential CD Diagnostic
  • Table 10: Market Potential DRNG Diagnostic
  • Table 11: Market Potential DRNTS Diagnostic
  • Table 12: Key AMR Diagnostics Issues
  • Table 13: The Global AMR Diagnostic Market by Country
  • Table 14: Global Market by Pathogen
  • Table 15: DRSP Diagnostics by Country
  • Table 16: DRC Diagnostics by Country
  • Table 17: CD Diagnostics by Country
  • Table 18: MRSA Diagnostics by Country
  • Table 19: DRNG Diagnostics by Country
  • Table 20: DRNTS Diagnostics by Country
  • Table 21: Global Market by Technology
  • Table 22: Culture Diagnostics by Country
  • Table 23: Immunoassay Diagnostics by Country
  • Table 24: PCR Diagnostics by Country
  • Table 25: NGS Diagnostics by Country
  • Table 26: MS Diagnostics by Country
  • Table 27: Rapid, POC and Other Diagnostics by Country

Table of Figures

  • Figure 1: Pharmaceutical Spending History by Country
  • Figure 2: AMR and Antibiotic Introduction
  • Figure 3: The Death Toll of AMR
  • Figure 4: AMR Diagnostics - Key Countries
  • Figure 5: Chart of Share Change by Pathogen
  • Figure 6: Pathogen Share by Year
  • Figure 7: Pathogen Segment Growth Rates
  • Figure 8: Chart - DRSP Segment vs Total Market
  • Figure 9: Chart - DRC Segment vs Total Market
  • Figure 10: Chart - CD segment vs Total Market
  • Figure 11: Chart - MRSA Segment vs Total Market
  • Figure 12: Chart - DRNG Segment vs Total Market
  • Figure 13: Chart - DRNTS Segment vs Total Market
  • Figure 14: Chart of Growth by Technology
  • Figure 15: Chart - Technology Change in Planning Period
  • Figure 16: Chart - Technology Share by Year
  • Figure 17: Chart - Bacterial Culture vs Total Market
  • Figure 18: Chart - Immunoassay vs Total Market
  • Figure 19: Chart - PCR vs Total Market
  • Figure 20: Chart - NGS vs Total Market
  • Figure 21: Chart - Mass Spectrometry vs Total Market
  • Figure 22: Chart - Rapid POC vs Total Market